Traws Pharma, Inc. Revenue Disclosure
6. Revenue
The Company recognized revenue under its license and collaboration agreement with SymBio as follows (See Note 14):
Year ended December 31, | ||||||
| 2023 |
| 2022 | |||
Symbio | ||||||
Upfront license fee recognition over time | $ | 226,000 | $ | 226,000 | ||
Deferred revenue is as follows:
Symbio | |||
| Upfront Payment | ||
Deferred balance at December 31, 2022 | $ | 3,243,000 | |
Recognition to revenue | (226,000) | ||
Deferred balance at December 31, 2023 | $ | 3,017,000 | |
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2023 | Apr 1, 2024 | Showing above |
| 2022 | Mar 30, 2023 | |
| 2021 | Mar 21, 2022 | |
| 2020 | Mar 18, 2021 | |
| 2019 | Mar 27, 2020 | |
| 2018 | Apr 1, 2019 | |
| 2017 | Mar 16, 2018 | |
| 2016 | Mar 29, 2017 | |
| 2015 | Mar 28, 2016 | |
About Revenue Disclosures
Revenue disclosures under ASC 606 explain how a company identifies performance obligations, allocates transaction prices, and determines when revenue is recognized. This section is essential for understanding whether reported revenue reflects genuine economic activity or aggressive accounting choices. Analysts examine the mix of point-in-time versus over-time recognition, which directly affects revenue timing and comparability.
Key signals: rising contract liabilities (deferred revenue) suggest strong future revenue visibility, while declining contract assets may indicate slowing project milestones. Watch for variable consideration estimates — rebates, returns, and performance bonuses that require management judgment. Significant changes in disaggregated revenue by geography or product line can reveal shifting business mix before it appears in headline numbers. Compare revenue growth against contract liability growth to assess sustainability, and scrutinize any changes in the timing of recognition that coincide with earnings pressure.